Cystic fibrosis is officially classified as a rare disease in both the United States and Europe. With roughly 40,000 people living with it in the U.S. and an estimated 162,000 worldwide, it falls well under the threshold of 200,000 affected individuals that the Orphan Drug Act uses to define a rare condition. That said, cystic fibrosis is one of the more common rare diseases, and its relatively higher visibility compared to other orphan conditions sometimes creates confusion about its status.
What Makes a Disease “Rare”
In the U.S., a disease qualifies as rare if it affects fewer than 200,000 people nationwide. That’s the legal definition set by the Orphan Drug Act, which was designed to encourage pharmaceutical companies to develop treatments for conditions that might not otherwise be profitable to pursue. Cystic fibrosis, with an estimated 38,800 to 40,000 people living with it in the U.S. as of 2020, is roughly one-fifth of the way to that ceiling. It qualifies comfortably.
Europe uses a slightly different metric, defining rare diseases as those affecting fewer than 1 in 2,000 people. Cystic fibrosis meets that standard as well. The rare disease classification in both regions has been pivotal for the CF community because it unlocks regulatory incentives, including tax credits, extended market exclusivity, and streamlined approval pathways, that make it financially viable for companies to develop targeted therapies.
How Common CF Actually Is
Globally, an estimated 162,428 people are living with cystic fibrosis across 94 countries. About 65% of them have been formally diagnosed, leaving an estimated 57,000 people who have the disease but don’t yet know it, largely in countries without robust newborn screening programs or patient registries.
CF is most common among people of Northern European descent. In the U.S., data from the Cystic Fibrosis Foundation Patient Registry shows that about 84% of registered patients are non-Hispanic white, 9% are Hispanic, 4.4% are Black or African American, and roughly 2.4% belong to other racial groups. This doesn’t mean CF is exclusive to white populations. It occurs across all ethnic backgrounds, but at lower rates, and people from minority groups are more likely to carry rarer genetic mutations that are harder to detect on standard screening panels.
The Genetics Behind It
Cystic fibrosis is inherited in an autosomal recessive pattern, meaning a child must receive one faulty copy of the responsible gene from each parent to develop the disease. If both parents are carriers (each having one working copy and one faulty copy), there’s a 25% chance with each pregnancy that the child will have CF, a 50% chance the child will be a carrier without symptoms, and a 25% chance the child will inherit two working copies.
The gene involved produces a protein that functions as a channel on the surface of cells, moving chloride (a component of salt) and water in and out. When the gene is defective, that channel either doesn’t work properly or isn’t made at all, causing the thick, sticky mucus that characterizes the disease. Scientists have identified over 1,950 different mutations in this gene since its discovery in 1989, which partly explains why the disease can vary so much in severity from person to person.
How CF Is Diagnosed
Most cases in the U.S. are now caught through newborn screening, which tests for markers in a blood sample taken shortly after birth. A positive screen leads to a sweat test, still considered the gold standard for diagnosis. The test measures the concentration of chloride in sweat: a level of 60 or higher strongly suggests cystic fibrosis, while a level between 30 and 59 falls into an intermediate range that requires further evaluation. Below 30 is considered normal. Genetic testing can confirm the diagnosis and identify the specific mutations involved, which matters because newer treatments target particular mutation types.
Why Rare Disease Status Matters for Treatment
The rare disease designation has been a major driver behind the wave of CF therapies that have transformed patient outcomes over the past decade. Roughly 1 in 10 drugs that receive orphan drug designation for CF eventually reach market approval, a ratio consistent with other rare diseases. But the composition of those drugs has shifted dramatically. In the earlier years of orphan drug development for CF, nearly 90% of designated therapies focused on managing symptoms like lung infections or nutritional deficiencies. In more recent years, that balance has flipped: closer to 38% of new designations now target the underlying protein defect itself, reflecting advances in understanding the genetics of the disease.
Financial realities still shape who can bring these treatments to market. Large pharmaceutical companies and those with prior experience in orphan drug development have been the most successful at moving drugs from designation to approval. Smaller companies often struggle with the costs of clinical trials and manufacturing, even with regulatory incentives in place.
Racial Disparities in Treatment Access
The newest class of CF treatments works by correcting or enhancing the defective protein, but they only work for patients who carry specific mutations. This creates an equity problem. About 88% of non-Hispanic white patients carry mutations eligible for the most effective combination therapy, compared to roughly 63% of Black patients, 67% of Hispanic patients, and 72% of patients from other racial groups. Black and African American patients are the least likely to carry mutations targeted by any currently available protein-correcting therapy.
Part of the issue is that minority patients are up to five times more likely to have mutations that haven’t been fully identified or classified. Because drug development has historically focused on the most common mutations, which predominate in white populations, patients carrying rarer variants have fewer treatment options. This gap is one of the more pressing challenges in CF care today.
Life Expectancy Has Changed Dramatically
A generation ago, most children with cystic fibrosis did not survive to adulthood. That picture has changed enormously. Based on 2024 registry data from the Cystic Fibrosis Foundation, a child born with CF between 2020 and 2024 has a median predicted survival age of 65 years. This is a population-level estimate and individual outcomes vary depending on mutation type, access to treatment, and other health factors. But it represents a remarkable shift from the single-digit life expectancies that defined the disease in the mid-20th century, driven largely by improvements in lung therapies, nutritional support, and the newer drugs that address the root cause of the disease.